Show simple item record

dc.contributor.authorMarcy, Olivier
dc.contributor.authorLaureillard, Didier
dc.contributor.authorMadec, Yoann
dc.contributor.authorChan, Sarin
dc.contributor.authorMayaud, Charles
dc.contributor.authorBorand, Laurence
dc.contributor.authorPrak, Narom
dc.contributor.authorKim, Chindamony
dc.contributor.authorLak, Kim Khemarin
dc.contributor.authorHak, Chanroeurn
dc.contributor.authorDim, Bunnet
dc.contributor.authorSok, Thim
dc.contributor.authorDelfraissy, Jean-François
dc.contributor.authorGoldfeld, Anne E
dc.contributor.authorBlanc, François-Xavier
dc.date.accessioned2014-12-11T22:47:59Z
dc.date.available2014-12-11T22:47:59Z
dc.date.issued2014-08
dc.identifier.citationCauses and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. 2014, 59 (3):435-45 Clin. Infect. Dis.en_GB
dc.identifier.issn1537-6591
dc.identifier.pmid24759827
dc.identifier.doi10.1093/cid/ciu283
dc.identifier.urihttp://hdl.handle.net/10144/337112
dc.description.abstractShortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.rightsArchived on this site with kind permission of Oxford University Press and thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB
dc.titleCauses and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trialen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB
refterms.dateFOA2019-03-04T11:39:44Z
html.description.abstractShortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.


Files in this item

Thumbnail
Name:
Marcy O - 2014 - Causes and ...
Size:
227.6Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record